HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II blood donors

Neurology

Volumn 48, Issue 2, 1997, Pages 315-320

  Murphy, Edward L ^a,h   Fridey, J ⁱ   Smith, J W ^b   Engstrom, J ^a   Sacher, R A ^c   Miller, K ^d   Gibble, J ^e   Stevens, J ^e   Thomson, R ^d   Hansma, D ^d   Kaplan, J ^f   Khabbaz, R ^f   Nemo, G ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Oklahoma Blood Institute   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WESTAT   (United States)

^e AMERICAN RED CROSS   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Box 0884 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROGENIC BLADDER; PRIORITY JOURNAL; RISK FACTOR; SPASTIC PARAPLEGIA;

EID: 0031038139     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.2.315     Document Type: Article

References (36)

1. Gessain A, Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1992;117:933-946.
2. Molgaard CA, Eisenman PA, Ryden LA, Golbeck AL. Neuroepidemiology of human T-lymphotropic virus type-I-associated spastic paraparesis. Neuroepidemiology 1989;8:109-123.
3. Osame M, Janssen R, Kubota H, et al. Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. Ann Neurol 1990;28:50-56.
4. Kramer A, Jacobson S, Reuben JF, et al. Spontaneous lymphocyte proliferation in symptom-free HTLV-I positive Jamaicans. Lancet 1989;2:923-924.
5. Harrison LH, Vaz B, Taveira DM, et al. Myelopathy among Brazilians coinfected with human T-cell lymphotropic virus type I and HIV. Neurology (in press).
6. Dixon PS, Bodner AJ, Okihiro M, et al. Human T-lymphotropic virus type I (HTLV-I) and tropical spastic paraparesis or HTLV-I-associated myelopathy in Hawaii. West J Med 1990;152:261-267.
7. Janssen RS, Kaplan JE, Khabbaz RF, et al. HTLV-I-associated myelopathy/tropical spastic paraparesis in the United States. Neurology 1991;41:1355-1357.
8. Sheremata WA, Berger JR, Harrington WJ, et al. Human T lymphotropic virus type I-associated myelopathy. Arch Neurol 1992;49:1113-1118.
9. Kawai H, Nishida Y, Sano Y, et al. HTLV-I-associated myelopathy (HAM) in Tokushima prefecture-geographical and clinical studies in an area between endemic and non-endemic areas of HTLV-I infection. Jpn J Med 1991;30:534-541.
10. Jeannel D, Garin B, Kazadi K, et al. The risk of tropical spastic paraparesis differs according to ethnic group among HTLV-I carriers in Inongo, Zaire. J Acquir Immune Defic Syndr 1993;6:840-844.
11. Kayembe K, Goubau P, Desmyter J, Vlietinck R, Carton H. A cluster of HTLV-I associated tropical spastic paraparesis in Equateur (Zaire): ethnic and familial distribution. J Neurol Neurosurg Psychiatry 1990;53:4-10.
12. Goubau P, Carton H, Kazadi K, Muay KW, Desmyter J. HTLV seroepidemiology in a central African population with high incidence of tropical spastic paraparesis. Trans R Soc Trop Med Hyg 1990;84:577-579.
13. Murphy EL, Wilks R, Morgan OS, et al. Health effects of human T-lymphotropic virus type I in a Jamaican cohort. Int J Epidemiol 1995;25:1090-1097.
14. World Health Organization. Virus Diseases: human T lymphotropic virus type I, HTLV-I. Weekly Epidemiological Record 1989;49:382.
15. Busch MP, Laycock M, Kleinman SH, et al. Accuracy of supplemental serologic testing for human T-lymphotropic virus (HTLV) types I and II in the United States blood donors. Blood 1994;83:1143-1148.
16. Gessain A, Caudie C, Gout O, et al. Intrathecal synthesis of antibodies to human T lymphotropic virus type I and the presence of IgG oligoclonal bands in the cerebrospinal fluid of patients with endemic tropical spastic paraparesis. J Infect Dis 1988;157:1226-1234.
17. Murphy EL, Engstrom JW, Miller K, et al. HTLV-II associated myelopathy in 43-year-old woman. Lancet 1993;341:757-758.
18. Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3:1096-1101.
19. Jacobson S, Lehky T, Nishimura M, Robinson S, McFarlin DE, Dhib-Jalbut S. Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 1993;33:392-396.
20. Harrington WJ Jr, Sheremata WA, Hjelle B, et al. Spastic ataxia associated with HTLV-II infection. Ann Neurol 1993; 33:411-414.
21. Hjelle B, Appenzeller O, Mills R, et al. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992;339:645-646.
22. Sheremata WA, Harrington WJ, Bradshaw PA, et al. Association of (tropical) ataxic neuropathy with HTLV-II. Virus Res 1993;29:71-77.
23. Dooneief G, Marlink R, Bell K, et al. Neurologic consequences of HTLV-II infection in injection drug users. Neurology 1996; 46:1556-1560.
24. Robert-Guroff M, Weiss SH, Giron JA, et al. Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA 1986;255:3133-3137.
25. Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, Chen ISY. High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 1989;244:471-475.
26. Feigal E, Murphy E, Vranizan K, et al. Human T cell lymphotropic virus type I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity. J Infect Dis 1991;164:36-42.
27. Osame M, Matsumoto M, Usuku K, et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia like cells. Ann Neurol 1987;21:117-122.
28. Rodgers-Johnson P, Morgan OS, Mora C, et al. The role of HTLV-I in tropical spastic paraparesis in Jamaica. Ann Neurol 1988;23(suppl):S121-S126.
29. Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990;322:383-388.
30. Ogata A, Nagashima K, Miyama A, Mikuni C. MRI-pathological correlate of brain lesions in a necropsy case of HTLV-I associated myelopathy. J Neurol Neurosurg Psychiatry 1993;56:194-196.
31. Kira J, Minato S, Itoyama Y, Goto I, Kato M, Hasuo K. Leukoencephalopathy in HTLV-I-associated myelopathy: MRI and EEG data. J Neurol Sci 1988;87:221-232.
32. Sasaki S, Komori T, Maruyama S, Takeishi M, Iwasaki Y. An autopsy case of human T lymphotropic virus type I-associated myelopathy (HAM) with a duration of 28 years. Acta Neuropathol (Berl) 1990;81:219-222.
33. Nomata K, Nakamura T, Suzu H, et al. Novel complications with HTLV-I-associated myelopathy/tropical spastic paraparesis: interstitial cystitis and persistent prostatitis. Jpn J Cancer Res 1992;83:601-608.
34. Bhagavati S, Ehrlich G, Kula RW, et al. Detection of human T-cell lymphoma/leukemia virus type I DNA and antigen in spinal fluid and blood of patients with chronic progressive myelopathy. N Engl J Med 1988;318:1141-1147.
35. Centers for Disease Control. Human T-lymphotropic virus type I screening in volunteer blood donors - United States, 1989. MMWR 39;1990:915-924.
36. Saito M, Kondo A, Kato K, Gotoh M. Bladder dysfunction due to human T-lymphotropic virus type I associated myelopathy. Br J Urol 1991;68:365-368.